C970 Stock Chart & Stats
€0.26
-€0.13(-13.68%)
At close: 4:00 PM EST
€0.26
-€0.13(-13.68%)
Day’s Range― - ―
52-Week Range€5.16 - €36.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€10.02M
Enterprise Value-€2.48M
Total Cash (Recent Filing)€8.23M
Total Debt (Recent Filing)€2.03M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-32.26
Shares Outstanding3,685,314
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.33
Price to Sales (P/S)10.83
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.36
Revenue Forecast (FY)€471.11K
Bulls Say, Bears Say
Bulls Say
India Manufacturing & Commercial PresenceCoSara's regulatory clearances and manufacturing license create durable market access across South Asia (~$13B TAM). Local production and an existing customer base support recurring consumable sales, lower regulatory friction and faster commercialization, enhancing long-term revenue opportunity and margin potential.
Completed Upper-respiratory Enrollment Enabling 510(k) PathA fully enrolled upper-respiratory study supports a formal 510(k) filing and CLIA-waived POC clearance, a structural step to access U.S. clinical and point-of-care markets. Regulatory clearance can unlock durable demand for assays and consumables and validate platform credibility with labs and providers.
Manufacturing Capacity & Automation ImprovementsAutomation plans that materially increase output and reduce unit labor underpin sustainable cost reduction and scale economics. A ~4x efficiency gain improves gross margin potential, supports higher-volume commercial rollouts, and lowers per-unit cost exposure over the medium term.
Bears Say
Severe Revenue Collapse And Loss Of ScaleThe precipitous revenue decline erodes fixed-cost absorption and destroys scale economics, making durable profitability contingent on successful product rollouts and volume recovery. With revenues at a negligible base, achieving sustainable margins requires multi-quarter execution and market adoption.
Persistent Cash Burn And Liquidity ShortfallSustained negative operating cash flow and a small cash balance create durable liquidity risk: the business needs new funding to execute regulatory filings, manufacturing build-outs and commercialization. Reliance on future capital raises increases execution uncertainty and can dilute stakeholders.
Execution And Timing Uncertainty For Strategic Deals And Build-outsUncertain outcomes and timelines for strategic transactions and facility build-outs pose structural execution risk. Delays or failed deals lengthen time to revenue, increase cash burn, and hinder the company's ability to achieve scale and realize benefits from local manufacturing and JV arrangements.
Co-Diagnostics News
C970 FAQ
What was Co-Diagnostics’s price range in the past 12 months?
Co-Diagnostics lowest stock price was €5.16 and its highest was €36.00 in the past 12 months.
What is Co-Diagnostics’s market cap?
Co-Diagnostics’s market cap is €10.02M.
When is Co-Diagnostics’s upcoming earnings report date?
Co-Diagnostics’s upcoming earnings report date is Aug 06, 2026 which is in 35 days.
How were Co-Diagnostics’s earnings last quarter?
Co-Diagnostics released its earnings results on May 14, 2026. The company reported -€3.56 earnings per share for the quarter, missing the consensus estimate of N/A by -€3.56.
Is Co-Diagnostics overvalued?
According to Wall Street analysts Co-Diagnostics’s price is currently Overvalued.
Does Co-Diagnostics pay dividends?
Co-Diagnostics does not currently pay dividends.
What is Co-Diagnostics’s EPS estimate?
Co-Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Co-Diagnostics have?
Co-Diagnostics has 3,685,314 shares outstanding.
What happened to Co-Diagnostics’s price movement after its last earnings report?
Co-Diagnostics reported an EPS of -€3.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Co-Diagnostics?
Currently, no hedge funds are holding shares in DE:C970
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Co-Diagnostics
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
C970 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated meaningful operational and regulatory progress across multiple strategic fronts — completed upper respiratory enrollment (>1,400 patients), India manufacturing license and expanded TAM (~$13B), TB clinical start timing, land allocation in Saudi Arabia, and manufacturing automation plans (~4x efficiency). However, the company still reports very limited absolute revenue, a negative gross margin, widening net loss and adjusted EBITDA losses, and a substantial cash decline to $8.2M with an anticipated need for additional capital. Program-level uncertainties (COVID prevalence affecting submission scope), unfinished manufacturing rollouts and no assurance on strategic transactions temper the positive operational milestones. Overall, operational momentum is clear, but financial constraints and execution risks balance the outlook.View all DE:C970 earnings summariesSintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
―
Heart Test Laboratories, Inc.
―
Options Prices
Currently, No data available
---